Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy and safety of Depemokimab in asthma with eosinophilic phenotype: a systematic review and meta-analysis of randomized controlled trials.

BMC immunology - 3 Dec 2025

Gill Basir Afzaal, Ijaz Anum, Fatima Noor, Ahmed Arsalan, Noor Ayesha, Sharif Samia, Fatima Ishrat, Saeeda Amna, Devi Hansa, Saddique Muhammad Nabeel

Abstract excerpt

INTRODUCTION: Asthma is a complex and heterogeneous disease that significantly impacts quality of life. Eosinophilic asthma, characterized by elevated eosinophil levels, leads to inflammation and hypersensitivity. Many patients remain inadequately managed, resulting in frequent exacerbations and hospitalizations despite standard treatment options. Depemokimab, a long-acting monoclonal antibody that targets IL-5,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Asthmatic Agents
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Asthma

Share to Eosinophilia

Share to Eosinophils

Share to Interleukin-5

Share to Quality of Life

Share to Randomized Controlled Trials as Topic

Source

Open in PubMed Open full text

Identifiers

PMID: 41331792
DOI: 10.1186/s12865-025-00777-6
PMCID: PMC12781320

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy and safety of Depemokimab in asthma with eosinophilic phenotype: a systematic review and meta-analysis of randomized controlled trials.PMID 41331792Read ↗

Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic PhenotypeSemantic proximity Read ↗

Mepolizumab real-world effectiveness in severe asthma with an eosinophilic phenotype and overlapping severe allergic asthma.Semantic proximity Read ↗

Mepolizumab for eosinophilic COPD with frequent exacerbations: single-centre real-world experience in a phenotype-directed approach.Semantic proximity Read ↗

Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic PhenotypeSemantic proximity Read ↗

Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotypeSemantic proximity Read ↗

Benralizumab for the add-on maintenance treatment of patients with severe asthma aged 12 years and older with an eosinophilic phenotype.Semantic proximity Read ↗

Monoclonal Antibodies in Idiopathic Chronic Eosinophilic Pneumonia: A Scoping ReviewSemantic proximity Read ↗

Eosinophilic phenotypes of airway disease.Semantic proximity Read ↗

Biologics in severe asthma: the overlap endotype - opportunities and challenges.Semantic proximity Read ↗

The effect of biologics on lung function improvements among severe eosinophilic asthma patients with partial reversibility or fixed obstructive defects: A retrospective analysisSemantic proximity Read ↗

The efficacy of omalizumab treatment in patients with non-atopic severe asthmaSemantic proximity Read ↗

Efficacy of Biologics in Aspirin Exacerbated Respiratory Disease: A Narrative ReviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.